Ashkan Shoamanesh: FDA Grants Asundexian A Priority Review for Secondary Stroke Prevention
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”Excellent news for patients with ischemic stroke and high-risk TIA: the U.S. FDA has granted Priority Review to asundexian for secondary stroke prevention based on the results of the OCEANIC-STROKE trial.
This marks an important step toward the potential rapid availability of a novel treatment strategy aimed at reducing recurrent ischemic events without increasing major bleeding risk – a long-standing unmet need in stroke prevention.
Very hopeful that other global regulatory agencies will follow suit so that patients worldwide may benefit from timely access to this therapy.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood
-
Jul 6, 2026, 17:382026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
-
Jul 6, 2026, 17:27Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
-
Jul 6, 2026, 17:15Sanchit Sharma։ Continuous Anticoagulation in PVT with Varices